09/08/2026
A significant milestone for PulseTech and Bangladesh’s startup ecosystem.
We sincerely appreciate Banglaverse EN for featuring Startup Bangladesh’s first-ever multi-fold investment return through PulseTech.
Thank you for recognizing this achievement and helping share our journey with a broader audience.
Read the full feature on:
https://www.facebook.com/share/p/19CwXNdbhu/?mibextid=wwXIfr
PulseTech delivers Startup Bangladesh’s first multi-fold return after revenue surge
The Dhaka pharma distribution startup grew annualised revenue to US$150 million while serving thousands of small pharmacies profitably
In young startup ecosystems, the first meaningful return matters almost as much as the cheque that produced it. It gives founders, investors and policymakers something more concrete than optimism: proof that local companies can grow fast, make money, and return capital.
Bangladesh has now reached one of those moments. Startup Bangladesh, the government-backed venture capital fund under the country’s ICT Division, has secured its first multi-fold investment return from PulseTech, a Dhaka-based pharmaceutical distribution startup that has grown from US$2 million to US$150 million in annualised revenue in two years.
The fund first invested in PulseTech in 2024. It has not disclosed the size of the original investment, the return multiple, or whether the transaction was a partial or full exit. Still, the development is notable for a market where venture-backed exits remain limited and where much of the startup narrative has, until recently, centred on funding access rather than capital recycling.
Startup Bangladesh was set up as a catalytic public venture fund to back technology companies solving local problems. It has invested in 36 startups since inception. For a government-sponsored vehicle, the PulseTech outcome is more than a portfolio update; it is a test case for whether public capital can help de-risk early companies and then draw in later private investors.
“At Startup Bangladesh, we invest with a purpose — to empower entrepreneurs solving real-world challenges while creating sustainable economic and social impact,” said Nurul Hai, MD and CEO of Startup Bangladesh. He added that the milestone “validates our catalytic investment approach” and reinforces the fund’s commitment to backing globally competitive Bangladeshi startups.
Fixing a fragmented medicine supply chain
PulseTech operates in a sector that is essential, large and messy. Bangladesh’s pharmaceutical market is worth about US$6 billion, according to the Bangladesh Investment Development Authority, but distribution remains fragmented. Independent pharmacies often buy from multiple suppliers or wholesale markets, creating inefficiencies in pricing, availability and delivery.
The bigger risk is trust. Fragmented supply chains can make it easier for counterfeit or substandard medicines to enter the market, especially when small retailers lack direct access to reliable distributors. This problem is familiar across many emerging Asian markets, including parts of Southeast Asia, where neighbourhood pharmacies still form a critical layer of healthcare access but often operate with limited technology and working capital.
PulseTech’s answer is MedBox, an app-based ordering and delivery network that allows small pharmacies to source authentic medicines through a licensed pharmaceutical distributor and receive same-day delivery. The company has layered additional services on top of this base, including embedded financing, pharmacy software and ONE Pharmacy, a franchise network that brings independent retailers under a shared brand.
That model gives PulseTech multiple ways to deepen its relationship with pharmacies. Distribution solves procurement. Software can help retailers manage stock and sales. Financing can give small operators the cash flow to buy inventory. Franchising, if executed well, can standardise parts of the retail experience without forcing independent owners to give up their businesses.
Since Startup Bangladesh’s initial investment, the company says it has maintained profitability while growing revenue at an average month-on-month rate of 20 per cent. It now serves more than 14,000 retail pharmacies in Dhaka, collectively reaching over 8.5 million people with what it describes as authentic, counterfeit-free medicines.
(In collaboration with PulesTech )
